Asia Tech Wire (May 17) -- Chinese pharmaceutical company WuXi Biologics (Cayman) Inc (2269.HK) said it does not pose safety risks to the U.S. or any other country.

WuXi Biologics said in a statement that it noted that the U.S. House Committee on Oversight and Accountability held a meeting on May 15 on, among other things, a revised draft of its biosafety bill (H.R. 8333).

It noted a number of differences between the draft and the previous version, including the removal of references related to the company's CEO Zhisheng Chen, who has been accused of having served at a Chinese military-affiliated organization.

The company said it also noted the revised draft bill's inclusion in the proposed definition of biotechnology company of concern, "a move that the company firmly believes is an unreasonable predetermined designation without due process."

WuXi Biologics said, "As a global biopharmaceutical CRDMO platform, the company neither has a human genomics business nor collects human genomic data in any of its global operations."

"The company reiterates that we have not posed, are not and will not pose a safety risk to the U.S. or any other country," it emphasized.

The Chinese company said, "As the legislative process related to the draft bill is still ongoing, its contents are still subject to further consideration of changes. The company will continue to closely monitor this process."

The U.S. House committee passed a revised version of the biosafety bill by a vote of 40-1 on Wednesday morning local time.

And the bill will then go to the U.S. House of Representatives for full consideration, discussion and a vote.